<DOC>
	<DOCNO>NCT01128985</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( blood level drug ) pharmacodynamics ( effect drug body ) canagliflozin oral administration patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Pharmacokinetic Pharmacodynamic Study Determine Blood Levels JNJ-28431754 ( Canagliflozin ) Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Canagliflozin drug test see may useful treat patient diagnose type 2 diabetes mellitus ( T2DM ) . This randomized ( patient assign 1 4 study treatment chance ) , double-blind ( neither patient study doctor know name assign treatment ) , study ass pharmacokinetics ( blood level ) pharmacodynamics ( effect drug body ) canagliflozin compare placebo ( capsule look like treatment real medicine ) patient T2DM . Approximately 36 patient T2DM receive once-daily treatment canagliflozin ( 50 mg , 100 mg , 300 mg dos ) placebo 7 day . Patients participate study approximately 9 week . Blood urine sample collect specified time dose study drug pharmacokinetic pharmacodynamic analysis . A blood sample also collect first dose study drug pharmacogenomic analysis ( ie , genetic testing ) possible use characterize safety and/or efficacy study drug relation patient pharmacogenic profile . During study , safety tolerability canagliflozin evaluate monitoring adverse event finding laboratory evaluation , vital sign measurement , ECG measurement . The primary outcome measure study concentration canagliflozin major metabolite ( M5 M7 ) blood measure protocol-specified pharmacokinetic parameter protocol specified time point Day 7 . Study drug take orally ( mouth ) daily first meal day . On Day -1 , patient take 1 dose placebo single-blind fashion ( patient blind ) determine baseline assessment . After randomization , patient take single dos double-blind canagliflozin ( 50 mg , 100 mg , 300 mg ) match placebo daily 7 day ( Day 1 Day 7 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>All patient must diagnosis T2DM least 1 year , 12 year prior Day 1 study medically stable basis physical examination , medical history , laboratory safety test result , vital sign electrocardiogram ( ECG ) perform Screening Patients must generally stable approve antihypeglycemic agent ( AHA ) regimen ( i.e. , change medication , 1 dose step change dose ) least 2 month prior Screening Visit Patients must fast plasma glucose ( FPG ) concentration 7.8 mM ( 140 mg/dL ) 15 mM ( 270 mg/dL ) Day 2 History clinically significant diabetic complication include retinopathy , nephropathy , macro albuminuria , neuropathy , gastroparesis , diabetic ketoacidosis History type 1 diabetes mellitus ( T1DM ) History repeat severe hypoglycemic episode screen</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacodynamic</keyword>
</DOC>